

ELATOSIDES A AND B, POTENT INHIBITORS OF ETHANOL ABSORPTION IN RATS FROM THE BARK OF *ARALIA ELATA* SEEM.: THE STRUCTURE-ACTIVITY RELATIONSHIPS OF OLEANOLIC ACID OLIGOGLYCOSIDES

Masayuki YOSHIKAWA,* Emiko HARADA, Hisashi MATSUDA, Toshiyuki MURAKAMI, Johji YAMAHARA, and Nobutoshi MURAKAMI


Kyoto Pharmaceutical University, 5 Nakauchi-cho, Misasagi, Yamashina-ku, Kyoto 607 Japan

By monitoring the inhibitory effect on ethanol absorption in rats, new active saponins named elatosides A and B were isolated from the bark of *Aralia elata* SEEM. together with elatosides C and D. The structures of elatosides A, B, C, and D were elucidated on the basis of chemical and physicochemical evidence. The inhibitory effects of several oleanolic acid oligoglycosides on ethanol absorption have been examined and some structure-activity relationships have been found.

KEYWORDS ethanol absorption inhibitory effect; structure-activity relationship; oleanolic acid oligoglycoside; elatoside A; elatoside B; *Aralia elata*

Alcoholism, which is a major health problem in the world, causes as much trouble physiologically as it does socially. Excessive consumption of ethanol is known to affect profoundly nearly every organ. The hitherto reported methods to relieve ethanol toxicity in acute alcohol ingestion are classified into two categories: 1) methods by sequestering of ethanol and ethanol-induced acetaldehyde in blood (e.g. D-penicillamine)¹⁾; 2) methods using accelerator of ethanol metabolism (e.g. clofibrate, γ -linolenic acid).²⁾ Recently, it has been reported that several plant extracts possessed the inhibitory activity on ethanol absorption,³⁾ but their active components have not been identified so far. In the course of our screening to find biologically active principles contained in Japanese and Chinese traditional medicine,⁴⁾ several crude drugs were found to contain inhibitors of ethanol absorption. This communication mainly deals with the results of studies on new inhibitors, elatosides A(1) and B(2), isolated from the bark of *Aralia elata* SEEM. (Araliaceae) and the structure-activity relationships in oleanolic acid oligoglycosides.⁵⁾

The bark and root cortex of *Aralia elata* SEEM. (Taranoki in Japanese) has been used in Japanese and Chinese traditional medicine as a tonic, anti-arthritic, and anti-diabetes agent. In regard to the chemical constituents of this plant, many saponins have been isolated from the roots⁶⁾ and leaves.⁷⁾ We have found that the MeOH extract of the bark of *Aralia elata* SEEM. collected in Kyoto Prefecture has an inhibitory effect on ethanol absorption in rats. The MeOH extract of the bark was partitioned into AcOEt-water, and the water-soluble portion was further extracted with 1-BuOH. The 1-BuOH-soluble portion of the inhibitory activity was subjected to ordinary and reversed phase SiO₂ column and HPLC to afford elatosides A (1, 0.0093% from the crude drug) and B(2, 0.0018%), spinasaponin A⁹⁾(5, 0.0041%) and stipuleanoside R₁¹⁰⁾(6, 0.0104%) from the active fractions. On the other hand, elatosides C(3, 0.0392%) and D(4, 0.0332%) and 7⁹⁾(0.0244%) and stipuleanoside R₂¹⁰⁾(8, 0.0301%) were isolated from the inactive fractions.



	R ¹	R ²	R ³	R ⁴
elatoside A (1):	β -D-Xyl	β -D-Gal	H	H
elatoside B (2):	β -D-Gal	β -D-Gal	H	H
elatoside C (3):	β -D-Xyl	β -D-Gal	H	β -D-Glu
elatoside D (4):	β -D-Gal	β -D-Gal	H	β -D-Glu
spinasaponin A (5):	H	β -D-Glu	H	H
stipuleanoside R ₁ (6):	H	β -D-Glu	α -L-Ara(f)	H
spinasaponin A 28-O-glucoside (7):	H	β -D-Glu	H	β -D-Glu
stipuleanoside R ₂ (8):	H	β -D-Glu	α -L-Ara(f)	β -D-Glu
chikusetsusaponin IVa (10):	H	H	H	H
11 :	H	H	α -L-Ara(f)	H
12 :	β -D-Glu	H	H	H
chikusetsusaponin IV (13):	H	H	α -L-Ara(f)	β -D-Glu
chikusetsusaponin V (14):	β -D-Glu	H	H	β -D-Glu

β -D-Xyl : β -D-xylopyranosyl
 β -D-Glu : β -D-glucopyranosyl

β -D-Gal : β -D-galactopyranosyl
 α -L-Ara(f) : α -L-arabinofuranosyl

Table I. Inhibitory Effects of Elatosides A(1), B(2), C(3), and D(4) and Other Oleanolic Acid Oligoglycosides (5, 6, 7, 8) from the Bark of *Aralia elata* SEEM. on Ethanol Absorption

	Dose (mg /kg, p.o.)	n	Ethanol concentration in blood (mg / ml)		
			1h	2h	3h
Elatoside A (1)	25	4	0.11±0.02**	0.13±0.05	0.02±0.00
	50	4	0.01±0.01**	0.04±0.02**	0.01±0.00
	100	5	0.00±0.00**	0.00±0.01**	0.00±0.00
Elatoside B (2)	25	5	0.56±0.01	0.19±0.02	0.01±0.00
	50	5	0.50±0.04	0.19±0.02	0.02±0.01
	100	5	0.25±0.10*	0.18±0.02	0.02±0.00
Elatoside C (3)	100	5	0.57±0.02	0.24±0.02	0.04±0.00
Elatoside D (4)	100	4	0.57±0.01	0.23±0.02	0.04±0.00
Spinasaponin A (5)	25	5	0.26±0.07*	0.20±0.04	0.03±0.01
	50	5	0.03±0.01**	0.04±0.02**	0.02±0.01
	100	4	0.03±0.02**	0.02±0.01**	0.01±0.00
Stipuleanoside R ₁ (6)	25	5	0.42±0.07	0.21±0.02	0.03±0.00
	50	4	0.34±0.09	0.18±0.03	0.01±0.00
	100	5	0.08±0.06**	0.09±0.04*	0.00±0.00
Spinasaponin A 28-O-glucoside(7)	100	3	0.58±0.01	0.21±0.00	0.00±0.00
Stipuleanoside R ₂ (8)	100	5	0.56±0.02	0.23±0.02	0.04±0.00
Control		8	0.56±0.01	0.16±0.01	0.00±0.00

* p<0.05, ** p<0.01

Table II. Inhibitory Effects of Chikusetsusaponins IVa(10), IV(13), and V (14), Prosapogenols (11, 12), and Oleanolic Acid(9) on Ethanol Absorption

	Dose (mg / kg, p.o.)	n	Ethanol concentration in blood (mg / ml)		
			1h	2h	3h
Oleanolic acid (9)	100	4	0.59±0.06	0.22±0.01	0.02±0.00
Chikusetsu- saponin IVa (10)	25	5	0.18±0.10*	0.14±0.03	0.01±0.01
	50	5	0.06±0.04**	0.07±0.03**	0.00±0.00
	100	5	0.06±0.02**	0.03±0.01**	0.01±0.00
11	25	5	0.21±0.09*	0.11±0.04	0.00±0.00
	50	5	0.02±0.01**	0.03±0.01**	0.00±0.00
	100	5	0.00±0.00**	0.02±0.01**	0.01±0.00
12	25	5	0.60±0.02	0.21±0.01	0.09±0.02
	50	5	0.50±0.05*	0.16±0.03	0.09±0.02
	100	4	0.06±0.02**	0.04±0.02**	0.02±0.00
Chikusetsu- saponin IV (13)	100	5	0.55±0.01	0.21±0.02	0.01±0.00
Chikusetsu- saponin V (14)	100	4	0.64±0.02	0.21±0.02	0.02±0.00
Control		10	0.61±0.02	0.18±0.02	0.05±0.01

* p<0.05, ** p<0.01

Elatoside A (1), colorless fine crystals mp 198.5-200.5°C, $[\alpha]_D +14.1^\circ$ (MeOH), $C_{47}H_{74}O_{18}$, IR(KBr): 3420, 2944, 1698 cm^{-1} , positive FAB-MS(m/z): 949(M+Na)⁺, gave oleanolic acid (9), methyl D-glucuronide, methyl D-galactoside, and methyl D-xyloside, upon methanolysis. The ¹H NMR (*d*₅-pyridine, J in Hz) and ¹³C NMR (Table III) data for 1 were assigned by ¹H-¹H COSY, ¹H-¹³C COSY, and Homonuclear Hartmann-Hahn spectroscopy (¹H-¹H HOHAHA, ¹H-¹³C HOHAHA): 4.95(m,¹¹) D-glucuronic acid 1'-H), 5.32(d, J=7.6, D-galactose 1'''-H), 5.54(d, J=7.2, D-xylose 1''-H). Comparison of the ¹³C NMR data for 1 with those for known oleanolic acid glucuronide-saponins (e.g. 5, 6, 10, 11, 12) led us to presume the oligosaccharide structure at 3-position in 1. Furthermore, the ROE was observed between 1'-H and 1''-H in the ROESY spectrum, so that the D-xylopyranosyl moiety of 1 was shown directly linked to 2'-hydroxyl group of D-glucuronopyranosyl moiety. Consequently, the structure of elatoside A (1) has been determined.

Elatoside B(2), colorless fine crystals, mp 186.0-187.0°C, $[\alpha]_D +15.3^\circ$ (MeOH), $C_{48}H_{76}O_{19}$, IR(KBr): 3430, 2946, 1698, ¹H NMR (*d*₅-pyridine, δ): 4.94(d, J = 7.2, D-glucuronic acid 1'-H), 5.31(d, J=7.6, D-galactose 1'''-H), 5.53(d, J=7.2, D-galactose 1''-H), positive FAB-MS(m/z): 979 (M+Na)⁺, gave 9 together with methyl D-glucuronide and methyl D-galactoside in a 1:2 ratio upon methanolysis. These findings together with the examination of ¹³C NMR data for 2 (Table III) led us to elucidate the structure of elatoside B (2).

The structures of elatoside C(3)¹² and elatoside D(4)¹³ have been elucidated in the same way. Based on the ¹H NMR and ¹³C NMR (Table III) analysis, it was concluded that 3 and 4 had the same oligoglycoside structure at 3-position as 1

and 2, respectively, regardless of the presence of 28-O-D-glucopyranosyl moiety. Upon methanolysis, 3 liberated 9, methyl D-glucuronide, methyl D-galactoside, methyl D-xyloside, and methyl D-glucoside, while 4 liberated 9, methyl D-glucuronide, methyl D-galactoside, and methyl D-glucoside. Alkaline hydrolysis of 3 and 4 with 5% aq. NaOH gave 1 and 2, respectively. Consequently, the structures of elatosides C(3) and D(4) were elucidated as shown.

Table III. ^{13}C NMR Data for 1, 2, 3, and 4 (68 MHz, d_5 -Pyridine, δc)

		1	2	3	4
3-O- β -D-Glucurono-pyranosyl moiety	1'	105.3	105.3	105.3	105.1
	2'	79.0	79.3	79.0	79.1
	3'	88.0	87.6	88.0	87.5
	4'	71.9	71.9	71.9	71.7
	5'	77.2	77.1	77.2	77.0
	6'	171.8	172.2	171.9	172.2
2'-O- β -D-Xylo- or galactopyranosyl moiety	1"	104.7	104.6	104.7	104.5
	2"	76.3	73.7	76.2	73.6
	3"	79.0	75.3	79.0	75.2
	4"	71.4	69.8	71.4	69.6
	5"	67.5	76.6	67.2	76.4
	6"		61.6		61.4
3'-O- β -D-Galactopyranosyl moiety	1'''	105.3	105.2	105.3	105.0
	2'''	72.9	72.9	72.9	72.8
	3'''	75.3	75.3	75.3	75.2
	4'''	70.1	70.2	70.1	70.0
	5'''	77.4	77.3	77.4	77.2
	6'''	62.0	62.0	62.0	62.0
28-O- β -D-Glucopyranosyl moiety	1''''			95.8	95.6
	2''''			74.2	74.0
	3''''			78.9	78.7
	4''''			71.1	70.9
	5''''			79.3	79.1
	6''''			62.2	61.8

REFERENCES AND NOTES

- H. T. Nagasawa, D. J. W. Goon, E. G. DeMaster, C. S. Alexander, *Life Sci.*, **20**, 187 (1977).
- S. Tsukamoto, Y. Hirakawa, S. Uchigasaki, T. Hatori, T. Kanegae, T. Nagoya, M. Shimamura, J. Tie, K. Yahiro, *Nihon Univ. J. Med.*, **34**, 43 (1992).
- a) S. Tsukamoto, T. Kanegae, T. Nagoya, T. Kato, S. Watabe, M. Kawaguchi, Abstract of Papers II, 112th Annual Meeting of the Pharmaceutical Society of Japan, Fukuoka, March 1992, p182; b) Y. J. Lee, C. B. Pantuck, *Planta Med.*, **59**, 17 (1993).
- M. Yoshikawa, Y. Fukuda, S. Hatakeyama, N. Tanaka, H. Matsuda, J. Yamahara, N. Murakami, *Chem. Pharm. Bull.*, **41**, 1194 (1993).
- M. Yoshikawa, E. Harada, Y. Kobori, S. Q. Liang, H. Matsuda, J. Yamahara, N. Murakami, presented at the 40th Annual Meeting of the Japanese Society of Pharmacognosy, Osaka, September 1993, Abstract of Papers, p82.
- a) T. Konishi, S. Sanada, Y. Ida, S. Shoji, Abstract of Papers, 101th Annual Meeting of the Pharmaceutical Society of Japan, Kumamoto, April 1981, p503; b) S. Sakai, Y. Ida, S. Shoji, Abstract of Papers, 107th Annual Meeting of the Pharmaceutical Society of Japan, Kyoto, April 1987, p338.
- a) S. Saito, S. Sumita, N. Tamura, Y. Nagamura, K. Nishida, M. Ito, I. Ishiguro, *Chem. Pharm. Bull.*, **38**, 411 (1990); b) S. Saito, J. Ebishi, S. Sumita, T. Fukumoto, Y. Nagamura, K. Nishida, I. Ishiguro, *ibid.*, **41**, 1395 (1993).
- R. Tschesche, H. Rehkaemper, G. Wulff, *Liebigs Ann. Chem.*, **726**, 125 (1969).
- G. Romussi, G. Bigrardi, *Arch. Pharm.*, **320**, 153 (1987).
- C. Yang, Z. Jiang, J. Zhou, R. Kasai, O. Tanaka, *Yunnan Zhiwu Yanjiu*, **7**, 103 (1985).
- a) This deformed signal pattern is attributable to the virtual long-range coupling^{11b, c)}; b) I. Kitagawa, M. Yoshikawa, K. S. Im, Y. Ikenishi, *Chem. Pharm. Bull.*, **25**, 657 (1979); c) J. I. Musher, E. J. Corey, *Tetrahedron*, **18**, 791 (1962).
- Elatoside C(3): colorless fine crystals, mp 208.5-209.5°C, $[\alpha]_D -1.6^\circ$ (MeOH), $\text{C}_{53}\text{H}_{84}\text{O}_{23}$, IR(KBr): 3389, 2946, 1734 cm^{-1} , ^1H NMR (d_5 -pyridine, δ): 4.94(br s,¹¹) D-glucuronic acid 1'-H), 5.31(d, J=7.6, D-galactose 1'''-H), 5.54(d, J=7.5, D-xylose 1"-H), 6.33(d, J = 7.9, D-glucose 1''''-H), positive FAB-MS(m/z): 1111 (M+Na)⁺.
- Elatoside D(4): colorless fine crystals, mp 188.5-189.5°C, $[\alpha]_D +6.9^\circ$ (MeOH), $\text{C}_{54}\text{H}_{86}\text{O}_{24}$, IR(KBr): 3367, 2946, 1734 cm^{-1} , ^1H NMR (d_5 -pyridine, δ): 4.82(d, J = 7.3, D-glucuronic acid 1'-H), 5.16(d, J=7.6, D-galactose 1'''-H), 5.39(d, J=7.6, D-galactose 1"-H), 6.19(d, J = 7.6, D-glucose 1''''-H), positive FAB-MS(m/z): 1141(M+Na)⁺.
- a) N. Kondo, J. Shoji, *Yakugaku Zasshi*, **88**, 325 (1968); b) N. Kondo, J. Shoji, N. Nagumo, K. Nomatsu, *ibid.*, **89**, 846 (1969); c) N. Kondo, Y. Marumoto, J. Shoji, *Chem. Pharm. Bull.*, **19**, 1103 (1971); d) T. D. Lin, N. Kondo, J. Shoji, *ibid.*, **24**, 253 (1976).

(Received September 21, 1993)